Philadelphia, Pennsylvania – July 28, 2025 – Minaris Advanced Therapies is pleased to announce the appointment of Luciana Mansolelli as Chief Quality Officer.
Luciana is a global quality and operations executive with over 29 years of leadership experience spanning development, manufacturing, quality, and corporate strategy. As Chief Quality Officer at Minaris Advanced Therapies, she champions quality as a competitive advantage in advancing cell and gene therapies and expanding patient access through robust, compliant, and innovative systems.
Prior to joining Minaris Advanced Therapies, Luciana has led global quality strategies across new and existing operations, shaping high-performing quality systems and guiding organizations through regulatory complexities. She has extensive experience engaging with global health authorities, industry councils, and standards bodies, contributing to the evolution of practices in risk management, technical transfer and ATMPs. She holds a PharmD and MBA in Innovation and Leadership.
With the recent addition of Luciana, Minaris Advanced Therapies now has a complete and dynamic executive leadership team marking a significant milestone in our Company’s growth and strategic direction.
Photo from left to right: (Top) – Prakash Manwani, Bill Burckardt, Eytan Abraham, Orla Cloak, Darwin Richardson, Ilya Koltover; (Seated) – Luciana Mansolelli, Rachel Collins Clarke, Kaia Boyd; (Not pictured) Hiroto Bando.
Our Executive Leadership Team includes:
- Orla Cloak, Ph.D. – Chief Executive Officer
- Eytan Abraham, Ph.D. – Chief Commercial and Technology Officer
- Hiroto Bando, Ph.D. – President, Japan
- Kaia Boyd – Chief Human Resources Officer
- Bill Burckardt – Chief Financial Officer
- Rachel Collins Clarke – Chief Legal Officer and General Counsel
- Ilya Koltover, Ph.D. – Chief Transformation Officer
- Luciana Mansolelli, PharmD – Chief Quality Officer
- Prakash Manwani – Chief Information Officer
- Darwin Richardson – Chief Operating Officer
Iain Baird, Chairman of the Board, Minaris Advanced Therapies, commented: “I am delighted to present a passionate and experienced team that is united in our objective of transforming Cell Therapy manufacturing to enable our client’s commercial success. This team brings a unique combination of strategic insight, industry experience, and a deep commitment to our clients which will guide us through our next chapter of growth and success”.
About Minaris Advanced Therapies:
Minaris Advanced Therapies is a global contract development and manufacturing organization and contract testing provider with a focus on cell and gene therapies. Minaris Advanced Therapies is headquartered in Philadelphia, Pennsylvania, and has more than 650,000 square feet of infrastructure across the United States, Europe and Asia. The organization has manufactured and released over 7,500 GMP batches and has a global network that supports therapy developers through early-stage development, clinical trials and commercial manufacturing.
Minaris Advanced Therapies is a portfolio company of Altaris.
About Altaris
Altaris is an investment firm with an exclusive focus on acquiring and building companies in the healthcare industry. Since its inception in 2003, Altaris has invested in more than 50 companies across a range of healthcare sub-sectors, with a consistent goal of delivering value to the healthcare system and generating attractive financial returns for investors. Altaris is headquartered in New York City and manages $10 billion of equity capital. For more information, please visit www.altariscap.com.
Media Contact:
Tihesha Aaron